Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia  Raul D. Santos, Frederick J. Raal,

Published byῬουβήν Ασπάσιος Modified over 5 years ago

Similar presentations

Presentation on theme: "Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia  Raul D. Santos, Frederick J. Raal,"— Presentation transcript:

1 Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia  Raul D. Santos, Frederick J. Raal, Joanne M. Donovan, William C. Cromwell  Journal of Clinical Lipidology  Volume 9, Issue 2, Pages (March 2015) DOI: /j.jacl Copyright © 2015 National Lipid Association Terms and Conditions

2 Figure 1 Study design for the 4 phase 3, randomized, double-blind, placebo-controlled trials of mipomersen in patients receiving maximally tolerated lipid-lowering therapy. * indicates ≤4-week screening period; † indicates 2:1 mipomersen 200 mg/wk versus placebo. Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

3 Figure 2 Median percentage change from baseline in total and subclasses of low-density lipoprotein particle (LDL-P) and intermediate-density lipoprotein particle (IDL-P) numbers for the mipomersen and placebo groups of all 4 phase 3 trials. HC-CHD, hypercholesterolemia and high risk for coronary heart disease study subjects; HeFH-CAD, heterozygous hypercholesterolemia and documented stable coronary artery disease study subjects; HoFH, homozygous familial hypercholesterolemia study subjects; Severe-HC, severe hypercholesterolemia study subjects. Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

Download ppt "Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia  Raul D. Santos, Frederick J. Raal,"

Similar presentations

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial  Arja T. Erkkilä, PhD, Ursula.

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial  Arja T. Erkkilä, PhD, Ursula.
Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.

Interrupting bile-acid handling and lipid and glucose control: Effects of colesevelam on glucose levels  Michael H. Davidson, MD  Journal of Clinical.
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,
Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels†  Eli.
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?  Raul D. Santos  Atherosclerosis.

What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?  Raul D. Santos  Atherosclerosis.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 

Charles R. Harper, MD, Terry A. Jacobson, MD  Mayo Clinic Proceedings 
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality  Rishi K. Wadhera,
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results.
My Approach to the Patient With Familial Hypercholesterolemia

My Approach to the Patient With Familial Hypercholesterolemia
Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Similar presentations

Ads by Google